A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5-period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300 microg) in patients with moderate to severe COPD [chronic obstructive pulmonary disease] using salbutamol (200 microg) and salmeterol/fluticasone (50/500 microg) as active controls.

Trial Profile

A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5-period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300 microg) in patients with moderate to severe COPD [chronic obstructive pulmonary disease] using salbutamol (200 microg) and salmeterol/fluticasone (50/500 microg) as active controls.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2014

At a glance

  • Drugs Indacaterol (Primary) ; Salbutamol; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
    • 12 Sep 2009 Status changed from recruiting to completed.
    • 26 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top